Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study
- PMID: 8806248
- PMCID: PMC2352037
- DOI: 10.1136/bmj.313.7057.591
Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study
Abstract
Objective: To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy.
Design: Observational follow up study of patients with insulin dependent diabetes and nephropathy who had been treated with captopril for a median of 7 years (range 3-9 years).
Setting: Outpatient diabetic clinic in a tertiary referral centre.
Patients: 35 patients with insulin dependent diabetes and nephropathy were investigated during captopril treatment (median 75 mg/day (range 12.5 to 150 mg/day)) that was in many cases combined with a loop diuretic, 11 patients were homozygous for the deletion allele and 24 were heterozygous or homozygous for the insertion allele of the angiotensin converting enzyme gene.
Main outcome measures: Albuminuria, arterial blood pressure, and glomerular filtration rate according to insertion/deletion polymorphism.
Results: The two groups had comparable glomerular filtration rate, albuminuria, blood pressure, and haemoglobin A1c concentration at baseline. Captopril induced nearly the same reduction in mean blood pressure in the two groups-to 103 (SD 5) mm Hg in the group with the deletion and 102 (8) mm Hg in the group with the insertion-and in geometric mean albumin excretion-573 (antilog SE 1.3) micrograms/min and 470 (1.2) micrograms/min, respectively. The rate of decline in glomerular filtration rate (linear regression of all glomerular filtration rate measurements during antihypertensive treatment) was significantly steeper in the group homozygous for the double deletion allele than in the other group (mean 5.7 (3.7) ml/min/year and 2.6 (2.8) ml/min/year, respectively; P = 0.01). Multiple linear regression analysis showed that haemoglobin A1c concentration, albuminuria, and the double deletion genotype independently influenced the sustained rate of decline in glomerular filtration rate (R1 (adjusted) = 0.51).
Conclusion: The deletion polymorphism in the angiotensin converting enzyme gene reduces the long term beneficial effect of angiotensin converting enzyme inhibition on the progression of diabetic nephropathy in patients with insulin dependent diabetes.
Comment in
-
Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy.BMJ. 1996 Dec 14;313(7071):1554-5. doi: 10.1136/bmj.313.7071.1554c. BMJ. 1996. PMID: 8978262 Free PMC article. No abstract available.
-
ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy.Nat Clin Pract Nephrol. 2008 Sep;4(9):472-3. doi: 10.1038/ncpneph0896. Epub 2008 Jul 22. Nat Clin Pract Nephrol. 2008. PMID: 18648343
Similar articles
-
[The significance of deletion polymorphism in the ACE gene for progression of diabetic nephropathies treated with ACE inhibitors].Ugeskr Laeger. 1998 Aug 17;160(34):4886-9. Ugeskr Laeger. 1998. PMID: 9741257 Danish.
-
Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.Nephrol Dial Transplant. 1997;12 Suppl 2:67-70. Nephrol Dial Transplant. 1997. PMID: 9269704
-
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.Kidney Int. 1998 Apr;53(4):1002-6. doi: 10.1111/j.1523-1755.1998.00847.x. Kidney Int. 1998. PMID: 9551410
-
The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.J Hypertens Suppl. 1989 Sep;7(7):S49-51. doi: 10.1097/00004872-198909007-00010. J Hypertens Suppl. 1989. PMID: 2575661 Review.
-
Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.J Cardiovasc Pharmacol. 1992;19 Suppl 6:S19-24. doi: 10.1097/00005344-199219006-00004. J Cardiovasc Pharmacol. 1992. PMID: 1382160 Review.
Cited by
-
Can ADAMTS13 lead us to the paradise of personalized medicine?Diabetes. 2013 Oct;62(10):3331-2. doi: 10.2337/db13-1055. Diabetes. 2013. PMID: 24065791 Free PMC article. No abstract available.
-
Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.Drugs. 1997 Jun;53(6):1081-105. doi: 10.2165/00003495-199753060-00010. Drugs. 1997. PMID: 9179532 Review.
-
Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.Drugs. 2004;64(16):1801-16. doi: 10.2165/00003495-200464160-00006. Drugs. 2004. PMID: 15301563 Review.
-
ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy.J Nephropathol. 2012 Oct;1(3):143-51. doi: 10.5812/nephropathol.8109. Epub 2012 Oct 1. J Nephropathol. 2012. PMID: 24475405 Free PMC article. Review.
-
Remission and regression of diabetic nephropathy.Curr Hypertens Rep. 2004 Oct;6(5):377-82. doi: 10.1007/s11906-004-0057-x. Curr Hypertens Rep. 2004. PMID: 15341691 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases